Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.66 |
| ▸ | TUBB | P07437 | 1/20 | 0.66 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.66 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.66 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.66 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.66 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.66 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.66 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.66 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.66 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.66 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.66 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.66 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 9/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854264 | 0.92 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3848175 | 0.90 | TUBB4A (0.63) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3151543 | 0.89 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Hydrochloric Acid SCHEMBL4920187 | 0.88 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3851419 | 0.87 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6093650 | 0.85 | TUBB4A (0.59) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28516015 | 0.84 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3845135 | 0.84 | TUBB4A (0.60) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3845507 | 0.82 | TUBB4A (0.76) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL3844095 | 0.82 | POLB (0.61) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809279-B1 | PARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INT (US) | 2013-05-29 | — | — | EP | claimed |
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | claimed |
| EP-1809279-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2007-07-25 | — | — | EP | claimed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | claimed |
| US-20060110462-A1 | Nanoparticulate compositions of tubulin inhibitor compounds | ZIOPHARM ONCOLOGY, INC. | 2006-05-25 | — | — | US | claimed |
| WO-2006052712-A1 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR | BAXTER INTERNATIONAL INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | BAXTER HEALTHCARE S.A. (CH) | 2003-11-06 | — | — | US | claimed |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | ZIOPHARM ONCOLOGY, INC. | 2002-10-31 | — | — | US | claimed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | claimed |
| US-7579365-B2 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ZIOPHRAM ONCOLOGY, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| EP-0931063-B3 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ZIOPHARM ONCOLOGY INC (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | ASTA MEDICA AKTIENGESELLSCHAFT | 2008-01-31 | — | — | US | disclosed |
| EP-0931063-B1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | BAXTER HEALTHCARE SA (CH) | 2006-10-18 | — | — | EP | disclosed |
| EP-1071420-B1 | INDOLYL-3-GLYOXYLIC ACID DERIVATIVES WITH ANTITUMORAL ACTIVITY | BAXTER HEALTHCARE SA (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6344467-B1 | ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSANT/IMMUNOMODULATING PROPERTIES | ASTA MEDICA AG (DE) | 2002-02-05 | — | — | US | disclosed |
| US-6232327-B1 | AND PHYSIOLOGICALLY TOLERABLE ACID ADDITION SALTS, N-OXIDES | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-05-15 | — | — | US | disclosed |
| US-6008231-A | ANTIALLERGENS, ANTIHISTAMINES, IMMUNOSUPPRESSANTS, IMMUNOMODULATORS | ASTA MEDICA AKTIENGESELLSCHGT (DE) | 1999-12-28 | — | — | US | disclosed |
| EP-0931063-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA Medica Aktiengesellschaft (DE) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009946-A1 | N-SUBSTITUTED INDOL-3-GLYOXYLAMID WITH ANTIASTHMATIC, ANTIALLERGIC AND IMMUNOSUPPRESSIVE/IMMUNOMODULATING EFFECT | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207892-A1 | N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | TUBB4A 3310/4885TUBB 3275/4885TUBA3C 2233/4885 |
| US-20080027110-A1 | Indolyl-3-glyoxylic acid derivatives having antitumor action | IDO1, IDO2, TDO2 | TUBB4A 2279/4885TUBB 1817/4885TUBA3C 1860/4885 |
| US-20020161025-A1 | N-substituted indole-3glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | IDO1, IDO2, INMT | TUBB4A 3117/4885TUBB 3238/4885TUBA3C 1665/4885 |
| US-20060110462-A1 | Nanoparticulate compositions of tubulin inhibitor compounds | TUBB, TUBB1, TUBB6 | TUBB4A 11/4885TUBB 1/4885TUBA3C 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.